Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer Sells 12,888 Shares

Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer sold 12,888 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. The trade was a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Evolus Stock Up 1.9 %

Shares of EOLS stock opened at $13.20 on Friday. The firm has a fifty day moving average of $13.10 and a 200-day moving average of $14.00. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a market capitalization of $839.35 million, a price-to-earnings ratio of -14.51 and a beta of 1.28.

Analysts Set New Price Targets

A number of equities analysts have commented on EOLS shares. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.

Institutional Trading of Evolus

A number of large investors have recently added to or reduced their stakes in EOLS. Tri Locum Partners LP acquired a new stake in Evolus in the fourth quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Evolus by 287.2% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock worth $7,753,000 after buying an additional 520,859 shares during the last quarter. Caligan Partners LP lifted its stake in shares of Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after buying an additional 498,900 shares during the last quarter. Allostery Investments LP acquired a new stake in shares of Evolus during the 4th quarter worth about $4,760,000. Finally, Altium Capital Management LLC lifted its stake in shares of Evolus by 93.0% during the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock worth $7,562,000 after buying an additional 330,000 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.